• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eledon Pharmaceuticals, Inc. - Common Stock (NQ:ELDN)

1.780 -0.120 (-6.32%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,294,686
Open 1.930
Bid (Size) 1.790 (300)
Ask (Size) 1.800 (1,500)
Prev. Close 1.900
Today's Range 1.760 - 2.000
52wk Range 1.350 - 4.490
Shares Outstanding 22,506,956
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights
November 12, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
October 26, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

52-Week Range 60.4% below 52-week high
1.780
1.3552W Low 4.4952W High
1 Week 19.8% below 1-week high
1.761W Low 2.221W High

Eledon Pharmaceuticals, Inc. - Common Stock (ELDN) traded between $1.35 and $4.49 over the past 52 weeks and last traded at $1.78, 60.4% below its 52-week high. Over the past week it ranged between $1.76 and $2.22.

Past 12 Months
-9.6%
-21.2%
-48.4%
-54.2%
+9.9%
+28.1%
1W -$0.19
1M -$0.48
3M -$1.67
6M -$2.11
YTD +$0.16
1Y +$0.39

ELDN was +28.1% over the past year, -54.2% over six months, +9.9% year to date, -9.6% in the last week.

12 Months vs Market
ELDN
+28.1%
DIA
+5.0%
SPY
+5.7%
QQQ
+3.9%
IWM
+12.0%

Over the past 12 months ELDN returned +28.1% versus DIA (Dow) +5.0%, SPY (S&P 500) +5.7%, QQQ (Nasdaq 100) +3.9% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 1.39× 3-mo avg
Today 1,294,686 3-mo avg 929.5K
1W
1.1M
1M
981.2K
3M
929.5K
6M
1.1M
YTD
1.1M
1Y
1.1M

ELDN most recently traded 1,294,686 shares against a 3-month average daily volume of 929.5K.

More News

Read More
News headline image
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
October 05, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
September 22, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Inc (NASDAQ:ELDN) Reports Narrower Q4 Loss and Positive Clinical Data for Tegoprubart ↗
March 19, 2026
Via Chartmill
News headline image
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
September 09, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
September 03, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
June 25, 2026
From Natera, Inc.
Via Business Wire
News headline image
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
June 22, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
June 08, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
June 04, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
May 20, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
March 19, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
March 16, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
March 10, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
March 04, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 05, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
January 23, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
January 08, 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
December 01, 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Tuesday's after hours session: top gainers and losers ↗
November 18, 2025
Via Chartmill
News headline image
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
November 18, 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
November 14, 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Eledon Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Eledon Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Eledon Pharmaceuticals, Inc. - Common Stock trade on?
Eledon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Eledon Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Eledon Pharmaceuticals, Inc. - Common Stock is ELDN on the Nasdaq Stock Market
What is the current price of Eledon Pharmaceuticals, Inc. - Common Stock?
The current price of Eledon Pharmaceuticals, Inc. - Common Stock is 1.780
When was Eledon Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Eledon Pharmaceuticals, Inc. - Common Stock was at 11/20/26 04:00 PM ET
What is the market capitalization of Eledon Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Eledon Pharmaceuticals, Inc. - Common Stock is 40.06M
How many shares of Eledon Pharmaceuticals, Inc. - Common Stock are outstanding?
Eledon Pharmaceuticals, Inc. - Common Stock has 40M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap